Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis

L. Hilakivi-Clarke, I. Onojafe, M. Raygada, E. Cho, Todd Skaar, I. Russo, R. Clarke

Research output: Contribution to journalArticle

169 Citations (Scopus)

Abstract

Prepubertal exposure to a pharmacological dose (500 mg kg-1) of the phyto-oestrogen genistein can reduce the incidence and multiplicity of carcinogen-induced mammary tumours in rats. However, such an exposure also disrupts the function of the hypothalamic-pituitary-gonadal axis, making it unsuitable for breast cancer prevention. We studied whether prepubertal exposure to genistein at a total body dose broadly comparable to the level typical of Oriental countries, approximately 1 mg kg-1 body weight, affects mammary tumorigenesis. We also studied whether prepubertal exposure to zearalenone, a major source for phyto-oestrogens in the USA, influences breast cancer risk. Prepubertal rats were treated between postnatal days 7 and 20, with 20 μg (~ 1 mg kg-1 body weight) of either genistein or zearalenone. Zearalenone exposure significantly reduced both the incidence and multiplicity of mammary tumours induced by 7,12-dimethylbenz(a)anthracene (DMBA). Genistein exposure significantly reduced tumour multiplicity, but not tumour incidence, when compared with vehicle-treated animals. Furthermore, 60% of the tumours in the genistein group were not malignant, while all the tumours analysed for histopathology in the vehicle and zearalenone groups were adenocarcinomas. A higher number of differentiated alveolar buds, and lower number of terminal ducts, were present in the DMBA-treated mammary glands of the phyto-oestrogen exposed rats. The concentration of oestrogen receptor (ER) binding sites after the DMBA treatment was low in the mammary glands of all groups but a significantly higher proportion of the glands in the zearalenone exposed rats were ER-positive (i.e. ER levels ≥ 5 fmol mg-1 protein) than the glands of the vehicle controls. Our data suggest that a prepubertal exposure to a low dose of either zearalenone or genistein may protect the mammary gland from carcinogen-induced malignant transformation, possibly by increasing differentiation of the mammary epithelial tree.

Original languageEnglish (US)
Pages (from-to)1682-1688
Number of pages7
JournalBritish Journal of Cancer
Volume80
Issue number11
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Zearalenone
Genistein
Carcinogenesis
Breast
Phytoestrogens
9,10-Dimethyl-1,2-benzanthracene
Human Mammary Glands
Breast Neoplasms
Carcinogens
Neoplasms
Incidence
Body Weight
Estrogen Receptors
Adenocarcinoma
Binding Sites
Pharmacology

Keywords

  • Genistein
  • Mammary tumorigenesis
  • Prepuberty
  • Zearalenone

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hilakivi-Clarke, L., Onojafe, I., Raygada, M., Cho, E., Skaar, T., Russo, I., & Clarke, R. (1999). Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis. British Journal of Cancer, 80(11), 1682-1688. https://doi.org/10.1038/sj.bjc.6690584

Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis. / Hilakivi-Clarke, L.; Onojafe, I.; Raygada, M.; Cho, E.; Skaar, Todd; Russo, I.; Clarke, R.

In: British Journal of Cancer, Vol. 80, No. 11, 1999, p. 1682-1688.

Research output: Contribution to journalArticle

Hilakivi-Clarke, L, Onojafe, I, Raygada, M, Cho, E, Skaar, T, Russo, I & Clarke, R 1999, 'Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis', British Journal of Cancer, vol. 80, no. 11, pp. 1682-1688. https://doi.org/10.1038/sj.bjc.6690584
Hilakivi-Clarke, L. ; Onojafe, I. ; Raygada, M. ; Cho, E. ; Skaar, Todd ; Russo, I. ; Clarke, R. / Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis. In: British Journal of Cancer. 1999 ; Vol. 80, No. 11. pp. 1682-1688.
@article{5fa72a2037e34680b5075fde46ddee3c,
title = "Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis",
abstract = "Prepubertal exposure to a pharmacological dose (500 mg kg-1) of the phyto-oestrogen genistein can reduce the incidence and multiplicity of carcinogen-induced mammary tumours in rats. However, such an exposure also disrupts the function of the hypothalamic-pituitary-gonadal axis, making it unsuitable for breast cancer prevention. We studied whether prepubertal exposure to genistein at a total body dose broadly comparable to the level typical of Oriental countries, approximately 1 mg kg-1 body weight, affects mammary tumorigenesis. We also studied whether prepubertal exposure to zearalenone, a major source for phyto-oestrogens in the USA, influences breast cancer risk. Prepubertal rats were treated between postnatal days 7 and 20, with 20 μg (~ 1 mg kg-1 body weight) of either genistein or zearalenone. Zearalenone exposure significantly reduced both the incidence and multiplicity of mammary tumours induced by 7,12-dimethylbenz(a)anthracene (DMBA). Genistein exposure significantly reduced tumour multiplicity, but not tumour incidence, when compared with vehicle-treated animals. Furthermore, 60{\%} of the tumours in the genistein group were not malignant, while all the tumours analysed for histopathology in the vehicle and zearalenone groups were adenocarcinomas. A higher number of differentiated alveolar buds, and lower number of terminal ducts, were present in the DMBA-treated mammary glands of the phyto-oestrogen exposed rats. The concentration of oestrogen receptor (ER) binding sites after the DMBA treatment was low in the mammary glands of all groups but a significantly higher proportion of the glands in the zearalenone exposed rats were ER-positive (i.e. ER levels ≥ 5 fmol mg-1 protein) than the glands of the vehicle controls. Our data suggest that a prepubertal exposure to a low dose of either zearalenone or genistein may protect the mammary gland from carcinogen-induced malignant transformation, possibly by increasing differentiation of the mammary epithelial tree.",
keywords = "Genistein, Mammary tumorigenesis, Prepuberty, Zearalenone",
author = "L. Hilakivi-Clarke and I. Onojafe and M. Raygada and E. Cho and Todd Skaar and I. Russo and R. Clarke",
year = "1999",
doi = "10.1038/sj.bjc.6690584",
language = "English (US)",
volume = "80",
pages = "1682--1688",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis

AU - Hilakivi-Clarke, L.

AU - Onojafe, I.

AU - Raygada, M.

AU - Cho, E.

AU - Skaar, Todd

AU - Russo, I.

AU - Clarke, R.

PY - 1999

Y1 - 1999

N2 - Prepubertal exposure to a pharmacological dose (500 mg kg-1) of the phyto-oestrogen genistein can reduce the incidence and multiplicity of carcinogen-induced mammary tumours in rats. However, such an exposure also disrupts the function of the hypothalamic-pituitary-gonadal axis, making it unsuitable for breast cancer prevention. We studied whether prepubertal exposure to genistein at a total body dose broadly comparable to the level typical of Oriental countries, approximately 1 mg kg-1 body weight, affects mammary tumorigenesis. We also studied whether prepubertal exposure to zearalenone, a major source for phyto-oestrogens in the USA, influences breast cancer risk. Prepubertal rats were treated between postnatal days 7 and 20, with 20 μg (~ 1 mg kg-1 body weight) of either genistein or zearalenone. Zearalenone exposure significantly reduced both the incidence and multiplicity of mammary tumours induced by 7,12-dimethylbenz(a)anthracene (DMBA). Genistein exposure significantly reduced tumour multiplicity, but not tumour incidence, when compared with vehicle-treated animals. Furthermore, 60% of the tumours in the genistein group were not malignant, while all the tumours analysed for histopathology in the vehicle and zearalenone groups were adenocarcinomas. A higher number of differentiated alveolar buds, and lower number of terminal ducts, were present in the DMBA-treated mammary glands of the phyto-oestrogen exposed rats. The concentration of oestrogen receptor (ER) binding sites after the DMBA treatment was low in the mammary glands of all groups but a significantly higher proportion of the glands in the zearalenone exposed rats were ER-positive (i.e. ER levels ≥ 5 fmol mg-1 protein) than the glands of the vehicle controls. Our data suggest that a prepubertal exposure to a low dose of either zearalenone or genistein may protect the mammary gland from carcinogen-induced malignant transformation, possibly by increasing differentiation of the mammary epithelial tree.

AB - Prepubertal exposure to a pharmacological dose (500 mg kg-1) of the phyto-oestrogen genistein can reduce the incidence and multiplicity of carcinogen-induced mammary tumours in rats. However, such an exposure also disrupts the function of the hypothalamic-pituitary-gonadal axis, making it unsuitable for breast cancer prevention. We studied whether prepubertal exposure to genistein at a total body dose broadly comparable to the level typical of Oriental countries, approximately 1 mg kg-1 body weight, affects mammary tumorigenesis. We also studied whether prepubertal exposure to zearalenone, a major source for phyto-oestrogens in the USA, influences breast cancer risk. Prepubertal rats were treated between postnatal days 7 and 20, with 20 μg (~ 1 mg kg-1 body weight) of either genistein or zearalenone. Zearalenone exposure significantly reduced both the incidence and multiplicity of mammary tumours induced by 7,12-dimethylbenz(a)anthracene (DMBA). Genistein exposure significantly reduced tumour multiplicity, but not tumour incidence, when compared with vehicle-treated animals. Furthermore, 60% of the tumours in the genistein group were not malignant, while all the tumours analysed for histopathology in the vehicle and zearalenone groups were adenocarcinomas. A higher number of differentiated alveolar buds, and lower number of terminal ducts, were present in the DMBA-treated mammary glands of the phyto-oestrogen exposed rats. The concentration of oestrogen receptor (ER) binding sites after the DMBA treatment was low in the mammary glands of all groups but a significantly higher proportion of the glands in the zearalenone exposed rats were ER-positive (i.e. ER levels ≥ 5 fmol mg-1 protein) than the glands of the vehicle controls. Our data suggest that a prepubertal exposure to a low dose of either zearalenone or genistein may protect the mammary gland from carcinogen-induced malignant transformation, possibly by increasing differentiation of the mammary epithelial tree.

KW - Genistein

KW - Mammary tumorigenesis

KW - Prepuberty

KW - Zearalenone

UR - http://www.scopus.com/inward/record.url?scp=0032774109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032774109&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6690584

DO - 10.1038/sj.bjc.6690584

M3 - Article

VL - 80

SP - 1682

EP - 1688

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 11

ER -